| Stephanie Margaret Peace, MD | |
|
385 Calle De Alegra Bldg C, Las Cruces, NM 88005-3423 | |
| (575) 556-8200 | |
| (575) 521-7199 |
| Full Name | Stephanie Margaret Peace |
|---|---|
| Gender | Female |
| Speciality | Gynecological Oncology |
| Experience | 7 Years |
| Location | 385 Calle De Alegra Bldg C, Las Cruces, New Mexico |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811423122 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mountain View Regional Medical Center | Las cruces, NM | Hospital |
| Memorial Medical Center | Las cruces, NM | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| La Clinica De Familia, Incorporated | 6305745191 | 56 |
News Archive
Medivir AB, a research-based pharmaceutical company focused on infectious diseases, announced today that a phase I clinical trial has been initiated with its investigational drug, MIV-711, a cathepsin K inhibitor for the treatment of bone disorders characterized by excessive bone resorption such as osteoporosis, osteoarthritis and bone metastases.
The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.
VIVUS, Inc. today announced that it held an End-of-Review meeting with the Food and Drug Administration (FDA) for the New Drug Application (NDA) for QNEXA®, an investigational drug for the treatment of obesity. The meeting occurred on January 19th at the FDA's offices in Maryland and was attended by senior members of the FDA and VIVUS' management and consultants.
Research from the University of Liverpool, published today in Lancet Respiratory Medicine, identifies a genetic variant that could improve the safety and effectiveness of corticosteroids, drugs that are used to treat a range of common and rare conditions including asthma, and chronic obstructive pulmonary disease (COPD).
In one of the largest studies of its kind, researchers at Orlando Health are making new progress in finding ways to detect a traumatic yet sinister brain injury - and getting closer to preventing further damage.
› Verified 6 days ago
| Entity Name | La Clinica De Familia, Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528424397 PECOS PAC ID: 6305745191 Enrollment ID: O20031231000076 |
News Archive
Medivir AB, a research-based pharmaceutical company focused on infectious diseases, announced today that a phase I clinical trial has been initiated with its investigational drug, MIV-711, a cathepsin K inhibitor for the treatment of bone disorders characterized by excessive bone resorption such as osteoporosis, osteoarthritis and bone metastases.
The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.
VIVUS, Inc. today announced that it held an End-of-Review meeting with the Food and Drug Administration (FDA) for the New Drug Application (NDA) for QNEXA®, an investigational drug for the treatment of obesity. The meeting occurred on January 19th at the FDA's offices in Maryland and was attended by senior members of the FDA and VIVUS' management and consultants.
Research from the University of Liverpool, published today in Lancet Respiratory Medicine, identifies a genetic variant that could improve the safety and effectiveness of corticosteroids, drugs that are used to treat a range of common and rare conditions including asthma, and chronic obstructive pulmonary disease (COPD).
In one of the largest studies of its kind, researchers at Orlando Health are making new progress in finding ways to detect a traumatic yet sinister brain injury - and getting closer to preventing further damage.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stephanie Margaret Peace, MD 385 Calle De Alegra Ste A, Las Cruces, NM 88005-3423 Ph: (575) 526-1105 | Stephanie Margaret Peace, MD 385 Calle De Alegra Bldg C, Las Cruces, NM 88005-3423 Ph: (575) 556-8200 |
News Archive
Medivir AB, a research-based pharmaceutical company focused on infectious diseases, announced today that a phase I clinical trial has been initiated with its investigational drug, MIV-711, a cathepsin K inhibitor for the treatment of bone disorders characterized by excessive bone resorption such as osteoporosis, osteoarthritis and bone metastases.
The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.
VIVUS, Inc. today announced that it held an End-of-Review meeting with the Food and Drug Administration (FDA) for the New Drug Application (NDA) for QNEXA®, an investigational drug for the treatment of obesity. The meeting occurred on January 19th at the FDA's offices in Maryland and was attended by senior members of the FDA and VIVUS' management and consultants.
Research from the University of Liverpool, published today in Lancet Respiratory Medicine, identifies a genetic variant that could improve the safety and effectiveness of corticosteroids, drugs that are used to treat a range of common and rare conditions including asthma, and chronic obstructive pulmonary disease (COPD).
In one of the largest studies of its kind, researchers at Orlando Health are making new progress in finding ways to detect a traumatic yet sinister brain injury - and getting closer to preventing further damage.
› Verified 6 days ago
Robert W Seaton, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 4351 E Lohman Ave, Suite 301, Las Cruces, NM 88011 Phone: 575-532-8900 Fax: 575-532-8963 | |
Dr. Virginia Deann Burnett, D.O. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 4345 Senna Dr, Las Cruces, NM 88011 Phone: 575-636-8854 | |
Dr. Rebecca Lynn Coalson, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 780 S Walnut St Bldg 1, Las Cruces, NM 88001 Phone: 575-521-1889 | |
Catherine T. Kemmer, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 2100 S Triviz Dr, Ste H, Las Cruces, NM 88001 Phone: 505-522-9793 Fax: 505-532-9019 | |
Dr. Kristen Renee Castillo, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 4351 E Lohman Ave Ste 401, Las Cruces, NM 88011 Phone: 575-522-4767 Fax: 575-522-3607 | |
Dr. Ismael Padilla Lopez, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 4351 E Lohman Ave Ste 408, Las Cruces, NM 88011 Phone: 575-532-7161 Fax: 575-522-3743 | |
Dr. Steven J. Lopez, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 385 Calle De Alegra Ste B, Las Cruces, NM 88005 Phone: 575-532-2044 Fax: 575-532-0807 |